Connecting Drug Delivery98

Issue No #98 Jun 2019 June 7th, 2019

Inside the magazine

CUSTOMISED INFUSION PUMPS: THE FUTURE OF SELF-ADMINISTRATION?

CUSTOMISED INFUSION PUMPS: THE FUTURE OF SELF-ADMINISTRATION?

Shaul Eitan explores the challenges of home infusion and examines how customisation and connectivity could help provide a solution.

I SPY WITH MY LITTLE EYE: EYE TRACKING DRIVES PATIENT-CENTRED DEVELOPMENT OF CONNECTED SYSTEMS

Dr Andreas Schneider

I SPY WITH MY LITTLE EYE: EYE TRACKING DRIVES PATIENT-CENTRED DEVELOPMENT OF CONNECTED SYSTEMS

The development of connected self-injection systems is driving industry to rethink its current approaches to patient-centred new product development. Andreas Schneider summarises a recent field study that used eye tracking for the formative usability testing of SmartPilot for YpsoMate.

MACRO TRENDS ACCELERATING THE ADOPTION OF CONNECTIVITY IN DRUG DELIVERY

Dr Ramin Rafiei

MACRO TRENDS ACCELERATING THE ADOPTION OF CONNECTIVITY IN DRUG DELIVERY

Ramin Rafiei argues that connected therapeutics – the augmentation of drugs through sensors and connectivity – are now a clinical source for real-world data and provide an opportunity to bridge the efficacy-to-effectiveness gap. This next frontier in drug delivery, powered by connected therapeutics, will be data-driven, personalised, outcomes-based and accessible.

COMPLETING ITS TRANSITION FROM GENESIS TO MATURITY, BIOCORP OPENS NEW HORIZONS

Eric Dessertenne

COMPLETING ITS TRANSITION FROM GENESIS TO MATURITY, BIOCORP OPENS NEW HORIZONS

As Biocorp prepares for the market launch of its connected injector pen add-on, Mallya, Eric Dessertenne and Arnaud Guillet share insights about key steps in the company’s development. The article discusses the many partnership Biocorp has entered in to, and includes a mini-interview with Sergio Monti, Plant Manager for one such partner, V.A.R.I.

CONNECTED DEVICES – MEDICATION DELIVERY JUST GOT PERSONAL

CONNECTED DEVICES – MEDICATION DELIVERY JUST GOT PERSONAL

Thierry Decock and Hadrien Gremillet explore how the obstacles to the adoption of connectivity can be overcome and how connected devices can deliver truly patient-centric care that will clearly improve adherence rates, whilst demonstrating a clear cost benefit to the pharmaceutical partner.

MIRCEA DESPA & DOUG McCLURE, BD

Dr Mircea Despa

BD (Becton Dickinson & Company)

MIRCEA DESPA & DOUG McCLURE, BD

In this interview, Dr Despa and Mr McClure discuss BD’s approach to connecting devices in its portfolio to meet patient, pharma and other stakeholder requirements. Their discussion focuses in particular on safety and security, highlighting the connected wearable injector, BD Libertas™ with Smart Option, as an example.

THE FUTURE OF CONNECTED ASTHMA AND COPD CARE: A NETWORK PERSPECTIVE

Dr Benjamin Jung

THE FUTURE OF CONNECTED ASTHMA AND COPD CARE: A NETWORK PERSPECTIVE

Benjamin Jung uses a network theory approach to look at the ongoing issue of adherence when it comes to the treatment of asthma and COPD, and the players involved in overcoming it.

CONNECTIVITY RESTORING TRUST IN PHARMA COMMUNICATIONS

Napoleon Monroe

CONNECTIVITY RESTORING TRUST IN PHARMA COMMUNICATIONS

Napoleon Monroe analyses connectivity coverage at recent drug delivery conferences and, more broadly, in various publications, to evaluate the current direction, and explore the scope for connectivity to effect changes benefiting multiple stakeholders across a range of treatment categories.

DON’T DEVELOP A CONNECTED DRUG DELIVERY DEVICE WITHOUT READING THIS

DON’T DEVELOP A CONNECTED DRUG DELIVERY DEVICE WITHOUT READING THIS

Matt Jones summarises some of the key challenges and opportunities in the development of connected drug delivery devices, focusing in detail on deciding what a connected drug delivery device should do, designing for a coin cell, direct cellular connection and antenna design.

USER-CENTRED DEVICE CONNECTIVITY

USER-CENTRED DEVICE CONNECTIVITY

Mark Tunkel and Carolyn Rose discuss the benefits of taking a user-needs approach, and mapping the patient journey, in a connectivity strategy.

PUSHING THE BOUNDARIES OF INFUSION PUMP INTEROPERABILITY

PUSHING THE BOUNDARIES OF INFUSION PUMP INTEROPERABILITY

Interoperability is not a new concept for infusion pumps. But in many cases hospitals have been slow to embrace the full potential of connectivity. When is this likely to change? What will hospitals need when it does? And where should infusion pump manufacturers focus innovation efforts in the meantime? Tim Frearson considers the options.

LOW-COST CONNECTIVITY MEETS PATIENT & PHARMA MEDICATION MANAGEMENT NEEDS

Phillips-Medisize

LOW-COST CONNECTIVITY MEETS PATIENT & PHARMA MEDICATION MANAGEMENT NEEDS

Neil Williams describes the potential connected drug delivery systems hold to address serious challenges in healthcare, including poor adherence, and also deliver substantial value, and outlines the company’s highly scalable enterprise platform, the Connected Health Platform.

ADHERENCE TO SELF-INJECTION REGIMENS CAN BE ENHANCED BY CONNECTED DEVICES

ADHERENCE TO SELF-INJECTION REGIMENS CAN BE ENHANCED BY CONNECTED DEVICES

Craig Baker looks at the factors contributing to non-adherence and explores how connected devices can help patients follow their self-injection regimens.

ADDING CONNECTIVITY TO DRUG DELIVERY DEVICES

E3D – Elcam Drug Delivery Devices

ADDING CONNECTIVITY TO DRUG DELIVERY DEVICES

Tsachi Shaked explores how – as the trend towards moving healthcare from the hospital to the home continues – connectivity in drug delivery devices may be changing from being the exception to the rule.